Canadian pharmaceutical conglomerate Valeant Pharmaceuticals International, Inc., parent of Bausch + Lomb, has agreed to divest Paragon Holdings I, Inc. to settle charges that its May 2015 acquisition of Paragon violated Section 7 of the Clayton Act and Section 5 of the Federal Trade Commission Act. Prior to the acquisition, both Valeant and an independent […]